FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition
- PMID: 11282421
- DOI: 10.1016/s0165-6147(00)01676-x
FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition
Abstract
Angiogenic growth factors such as fibroblast growth factors (FGFs) and vascular endothelial growth factors (VEGFs) are currently targets of intense efforts to inhibit deregulated blood vessel formation in diseases such as cancer. FGFs and VEGFs exert their effects via specific binding to cell surface-expressed receptors equipped with tyrosine kinase activity. Activation of the receptor kinase activity allows coupling to downstream signal transduction pathways that regulate proliferation, migration and differentiation of endothelial cells. Inhibitors of FGF and VEGF signalling are currently in clinical trials. In this article, the current knowledge of FGF- and VEGF-induced signal transduction that leads to specific biological responses will be summarized. Furthermore, the manner in which this knowledge is being exploited to regulate angiogenesis will be discussed.
Similar articles
-
Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis.Crit Rev Oncol Hematol. 2000 Jun;34(3):185-94. doi: 10.1016/s1040-8428(00)00062-7. Crit Rev Oncol Hematol. 2000. PMID: 10838264 Review.
-
Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects.Semin Oncol. 2002 Jun;29(3 Suppl 11):104-10. doi: 10.1053/sonc.2002.34062. Semin Oncol. 2002. PMID: 12138404 Review.
-
VEGF: an update on biological and therapeutic aspects.Curr Opin Biotechnol. 2000 Dec;11(6):617-24. doi: 10.1016/s0958-1669(00)00153-1. Curr Opin Biotechnol. 2000. PMID: 11102799 Review.
-
Divergence of angiogenic and vascular permeability signaling by VEGF: inhibition of protein kinase C suppresses VEGF-induced angiogenesis, but promotes VEGF-induced, NO-dependent vascular permeability.Arterioscler Thromb Vasc Biol. 2002 Jun 1;22(6):901-6. doi: 10.1161/01.atv.0000020006.89055.11. Arterioscler Thromb Vasc Biol. 2002. PMID: 12067896
-
Therapeutic angiogenesis for ischemic cardiovascular disease.J Mol Cell Cardiol. 2001 Mar;33(3):379-93. doi: 10.1006/jmcc.2000.1329. J Mol Cell Cardiol. 2001. PMID: 11181008 Review.
Cited by
-
Comprehensive multi-omics analysis and prognostic significance of fibroblast growth factor binding protein 1 (FGFBP1) in pancreatic adenocarcinoma.Am J Transl Res. 2024 Aug 15;16(8):4101-4119. doi: 10.62347/NCRX9798. eCollection 2024. Am J Transl Res. 2024. PMID: 39262727 Free PMC article.
-
Therapeutic potential of growth factors in pulmonary emphysematous condition.Lung. 2013 Apr;191(2):147-63. doi: 10.1007/s00408-012-9438-0. Epub 2012 Nov 17. Lung. 2013. PMID: 23161370 Review.
-
Vascular endothelial cell-specific microRNA-15a inhibits angiogenesis in hindlimb ischemia.J Biol Chem. 2012 Aug 3;287(32):27055-64. doi: 10.1074/jbc.M112.364414. Epub 2012 Jun 12. J Biol Chem. 2012. PMID: 22692216 Free PMC article.
-
Generation of FGF reporter transgenic zebrafish and their utility in chemical screens.BMC Dev Biol. 2007 Jun 6;7:62. doi: 10.1186/1471-213X-7-62. BMC Dev Biol. 2007. PMID: 17553162 Free PMC article.
-
Serum VEGF and b-FGF profiles after tension-free or conventional hernioplasty.Langenbecks Arch Surg. 2005 Nov;390(6):528-33. doi: 10.1007/s00423-005-0578-z. Epub 2005 Sep 23. Langenbecks Arch Surg. 2005. PMID: 16180047 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical